CRVO
CervoMed Inc.
Price Chart
Latest Quote
$4.24
+0.43 (+11.29%)
Current Price
| Previous Close | $3.81 |
| Open | $4.68 |
| Day High | $7.81 |
| Day Low | $3.84 |
| Volume | 107,435,282 |
Stock Information
| Shares Outstanding | 9.26M |
| Cash Equivalents | $12.92M |
| Revenue | $2.09M |
| Net Income | $-30.04M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $39.26M |
| EPS (TTM) | $-3.30 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $26.33M |
| Sales | $2.09M |
| Income | $-30.04M |
| Book/sh | $1.15 |
| Cash/sh | $1.40 |
| Employees | 15 |
Financial Ratios
| Quick Ratio | 2.87 |
| Current Ratio | 3.36 |
Returns & Margins
| ROA | -72.41% |
| ROE | -132.76% |
| Operating Margin | -1488.86% |
Ownership
| Insider Ownership | 43.16% |
| Institutional Ownership | 19.43% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.75 |
| P/S | 18.79 |
| P/B | 3.70 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $19.50 |
Technical Indicators
| SMA20 | $3.08 |
| SMA50 | $3.48 |
| SMA200 | $6.02 |
| RSI | 62.36 |
| ATR | 0.9071 |
| Shares Float | 5.34M |
| Short Float | 4.13% |
| Short Ratio | 4.00 |
| Volatility | -4.54 |
| Rel Volume | 6.63 |
Performance History
| Week | +73.77% |
| Month | +46.71% |
| Quarter | +0.24% |
| 6 Months | -49.22% |
| YTD | -45.57% |
| Year | -39.94% |
| 3 Years | -19.70% |
| 5 Years | -92.84% |
| 10 Years | -99.96% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $4.24 | 107,909,200 |
| 2026-06-17 | $3.81 | 5,254,800 |
| 2026-06-16 | $4.52 | 200,678,200 |
| 2026-06-15 | $2.48 | 9,533,400 |
| 2026-06-12 | $2.45 | 131,800 |
| 2026-06-11 | $2.44 | 185,200 |
| 2026-06-10 | $2.25 | 1,087,100 |
| 2026-06-09 | $2.89 | 30,600 |
| 2026-06-08 | $2.91 | 21,800 |
| 2026-06-05 | $2.94 | 62,200 |
| 2026-06-04 | $3.12 | 45,300 |
| 2026-06-03 | $2.97 | 43,300 |
| 2026-06-02 | $3.00 | 27,600 |
| 2026-06-01 | $3.00 | 94,700 |
| 2026-05-29 | $3.11 | 75,400 |
| 2026-05-28 | $3.14 | 32,200 |
| 2026-05-27 | $3.04 | 68,500 |
| 2026-05-26 | $3.05 | 114,800 |
| 2026-05-22 | $3.06 | 102,000 |
| 2026-05-21 | $3.09 | 68,500 |
| 2026-05-20 | $3.24 | 97,200 |
| 2026-05-19 | $2.89 | 113,700 |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodÂbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
đ° Latest News
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally
Stocktwits âĸ 2026-06-18T17:55:00Z
Top Midday Gainers
MT Newswires âĸ 2026-06-18T17:32:19ZCervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)
InvestorsHub âĸ 2026-06-18T14:08:36Z
CervoMed Insiders Lose Out As Stock Sinks To US$2.45
Simply Wall St. âĸ 2026-06-14T12:14:29Z
Why Did CRVO Stock Crash 22% In Pre-Market Trading Today?
Stocktwits âĸ 2026-06-10T12:34:56Z
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T23:05:24Z
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-05T11:10:02Z
CervoMed (CRVO)âs Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)
Insider Monkey âĸ 2026-03-25T19:28:18Z
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-13T22:15:01Z
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
Zacks âĸ 2026-03-03T13:07:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $28,294,877 | $18,227,131 | $7,812,895 | $3,475,534 |
| Other Income Expense | $-8,327 | $-991 | $5,421,592 | $-2,389,152 |
| Other Non Operating Income Expenses | $-8,327 | $-991 | $5,421,592 | $-2,389,152 |
| Net Non Operating Interest Income Expense | $1,336,837 | $1,937,427 | $219,430 | $61,639 |
| Operating Expense | $28,294,877 | $18,227,131 | $7,812,895 | $3,475,534 |
| Other Operating Expenses | $-4,006,510 | $-9,737,974 | $-7,144,872 | - |
| General And Administrative Expense | $10,484,315 | $9,166,762 | $6,519,268 | $2,139,065 |
| Interest Expense | - | - | $0 | $587 |
| Interest Expense Non Operating | - | - | $0 | $587 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,966,367 | $-16,290,695 | $-2,171,873 | $-5,803,047 |
| Net Interest Income | $1,336,837 | $1,937,427 | $219,430 | $61,639 |
| Interest Income | $1,336,837 | $1,937,427 | $219,430 | $62,226 |
| Normalized Income | $-26,966,367 | $-16,290,695 | $-2,171,873 | $-5,803,047 |
| Net Income From Continuing And Discontinued Operation | $-26,966,367 | $-16,290,695 | $-2,171,873 | $-5,803,047 |
| Total Operating Income As Reported | $-28,294,877 | $-18,227,131 | $-7,812,895 | $-3,475,534 |
| Net Income Common Stockholders | $-26,966,367 | $-16,290,695 | $-2,171,873 | $-5,803,047 |
| Net Income | $-26,966,367 | $-16,290,695 | $-2,171,873 | $-5,803,047 |
| Net Income Including Noncontrolling Interests | $-26,966,367 | $-16,290,695 | $-2,171,873 | $-5,803,047 |
| Net Income Continuous Operations | $-26,966,367 | $-16,290,695 | $-2,171,873 | $-5,803,047 |
| Pretax Income | $-26,966,367 | $-16,290,695 | $-2,171,873 | $-5,803,047 |
| Interest Income Non Operating | $1,336,837 | $1,937,427 | $219,430 | $62,226 |
| Operating Income | $-28,294,877 | $-18,227,131 | $-7,812,895 | $-3,475,534 |
| Special Income Charges | - | - | - | $0 |
| Depreciation Amortization Depletion Income Statement | - | - | - | $0 |
| Depreciation And Amortization In Income Statement | - | - | - | $0 |
| Depreciation Income Statement | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-2.98 | $-2.02 | $-0.82 | $-11.20 |
| Basic EPS | $-2.98 | $-2.02 | $-0.82 | $-11.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-28,294,877 | $-18,227,131 | $-7,812,895 | $-5,802,460 |
| EBITDA (Bullshit earnings) | $-28,294,877 | $-18,227,131 | $-7,812,895 | $-5,802,460 |
| EBIT | $-28,294,877 | $-18,227,131 | $-7,812,895 | $-5,802,460 |
| Diluted Average Shares | $9,041,760 | $8,073,155 | $2,661,416 | $518,140 |
| Basic Average Shares | $9,041,760 | $8,073,155 | $2,661,416 | $518,140 |
| Diluted NI Availto Com Stockholders | $-26,966,367 | $-16,290,695 | $-2,171,873 | $-5,803,047 |
| Research And Development | $21,817,072 | $18,798,343 | $8,438,499 | $1,336,469 |
| Selling General And Administration | $10,484,315 | $9,166,762 | $6,519,268 | $2,139,065 |
| Other Gand A | $10,484,315 | $9,166,762 | $6,519,268 | $2,139,065 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Reconciled Depreciation | - | - | - | $0 |
| Tax Provision | - | - | - | $0 |
| Impairment Of Capital Assets | - | - | - | $0 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $18,222,901 | $39,202,328 | $7,376,774 | $-33,285,059 |
| Total Assets | $22,879,018 | $43,081,610 | $9,972,521 | $4,157,706 |
| Total Non Current Assets | $0 | $0 | $7,770 | $0 |
| Current Assets | $22,879,018 | $43,081,610 | $9,964,751 | $4,157,706 |
| Current Deferred Assets | $320,581 | $0 | - | - |
| Prepaid Assets | $1,267,005 | $1,905,360 | $1,256,501 | $64,127 |
| Receivables | $426,993 | $2,254,231 | $915,404 | $0 |
| Other Receivables | $426,993 | $2,254,231 | $915,404 | - |
| Cash Cash Equivalents And Short Term Investments | $20,864,439 | $38,922,019 | $7,792,846 | $4,093,579 |
| Cash And Cash Equivalents | $8,235,469 | $8,999,496 | $7,792,846 | $4,093,579 |
| Other Non Current Assets | - | - | $7,770 | - |
| Cash Equivalents | - | - | $7,792,846 | $4,093,579 |
| Other Current Assets | - | - | - | $112,406 |
| Cash Financial | - | - | - | $1,586,920 |
| Goodwill And Other Intangible Assets | - | - | - | - |
| Debt | ||||
| Net Debt | - | - | - | $8,320,421 |
| Total Debt | - | - | - | $12,414,000 |
| Current Debt And Capital Lease Obligation | - | - | - | $12,414,000 |
| Current Debt | - | - | - | $12,414,000 |
| Other Current Borrowings | - | - | - | $12,414,000 |
| Long Term Debt And Capital Lease Obligation | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,656,117 | $3,879,282 | $2,595,747 | $37,442,765 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $24,287,211 |
| Current Liabilities | $4,656,117 | $3,879,282 | $2,595,747 | $13,155,554 |
| Other Current Liabilities | $83,383 | $115,883 | $88,659 | $129,851 |
| Payables And Accrued Expenses | $3,510,968 | $2,960,206 | $1,481,034 | $377,484 |
| Payables | $1,494,574 | $1,551,896 | $782,927 | $97,302 |
| Total Tax Payable | $40,456 | $40,456 | $120,456 | $0 |
| Accounts Payable | $1,454,118 | $1,511,440 | $662,471 | $97,302 |
| Non Current Deferred Liabilities | - | - | - | - |
| Non Current Deferred Taxes Liabilities | - | - | - | - |
| Equity | ||||
| Total Equity Gross Minority Interest | $18,222,901 | $39,202,328 | $7,376,774 | $-33,285,059 |
| Stockholders Equity | $18,222,901 | $39,202,328 | $7,376,774 | $-33,285,059 |
| Gains Losses Not Affecting Retained Earnings | $5,816 | $56,197 | $0 | $-35,375 |
| Other Equity Adjustments | $5,816 | $56,197 | - | $-35,375 |
| Retained Earnings | $-97,697,851 | $-70,731,484 | $-54,440,789 | $-52,268,916 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $24,287,211 |
| Common Stock Equity | - | - | - | $-33,285,059 |
| Other | ||||
| Ordinary Shares Number | $9,252,719 | $8,702,719 | $5,674,520 | $1,359,704 |
| Share Issued | $9,252,719 | $8,702,719 | $5,674,520 | $1,359,704 |
| Tangible Book Value | $18,222,901 | $39,202,328 | $7,376,774 | $-33,285,059 |
| Invested Capital | $18,222,901 | $39,202,328 | $7,376,774 | $-20,871,059 |
| Working Capital | $18,222,901 | $39,202,328 | $7,369,004 | $-8,997,848 |
| Total Capitalization | $18,222,901 | $39,202,328 | $7,376,774 | $-33,285,059 |
| Additional Paid In Capital | $115,905,684 | $109,868,913 | $61,811,889 | $18,983,339 |
| Capital Stock | $9,252 | $8,702 | $5,674 | $518 |
| Common Stock | $9,252 | $8,702 | $5,674 | $518 |
| Preferred Stock | $0 | $0 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $1,061,766 | $803,193 | $1,026,054 | $364,070 |
| Current Accrued Expenses | $2,016,394 | $1,408,310 | $698,107 | $280,182 |
| Other Short Term Investments | $12,628,970 | $29,922,523 | $0 | $12,408,940 |
| Capital Lease Obligations | - | - | - | - |
| Long Term Capital Lease Obligation | - | - | - | - |
| Current Capital Lease Obligation | - | - | - | - |
| Net PPE | - | - | - | - |
| Gross PPE | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-23,449,963 | $-16,530,827 | $-7,449,847 | $-2,572,759 |
| Operating Activities | ||||
| Operating Cash Flow | $-23,449,963 | $-16,530,827 | $-7,449,847 | $-2,572,759 |
| Cash Flow From Continuing Operating Activities | $-23,449,963 | $-16,530,827 | $-7,449,847 | $-2,572,759 |
| Operating Gains Losses | - | - | - | $127,516 |
| Investing Activities | ||||
| Investing Cash Flow | $18,097,249 | $-28,661,129 | $0 | $-12,235,738 |
| Cash Flow From Continuing Investing Activities | $18,097,249 | $-28,661,129 | $0 | $-12,235,738 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $4,588,687 | $46,398,606 | $810,000 | $0 |
| Financing Cash Flow | $4,588,687 | $46,398,606 | $11,149,114 | $0 |
| Cash Flow From Continuing Financing Activities | $4,588,687 | $46,398,606 | $11,149,114 | $0 |
| Net Common Stock Issuance | $4,588,687 | $46,398,606 | $810,000 | $0 |
| Common Stock Issuance | $4,588,687 | $46,398,606 | $810,000 | $0 |
| Net Other Financing Charges | - | - | $10,339,114 | - |
| Net Preferred Stock Issuance | - | - | - | $5,000 |
| Preferred Stock Issuance | - | - | - | $5,000 |
| Other | ||||
| End Cash Position | $8,235,469 | $8,999,496 | $7,792,846 | $4,093,579 |
| Beginning Cash Position | $8,999,496 | $7,792,846 | $4,093,579 | $6,666,338 |
| Changes In Cash | $-764,027 | $1,206,650 | $3,699,267 | $-2,572,759 |
| Net Investment Purchase And Sale | $18,097,249 | $-28,661,129 | $0 | $-12,235,738 |
| Sale Of Investment | $43,500,000 | $19,440,000 | $0 | $25,750,000 |
| Purchase Of Investment | $-25,402,751 | $-48,101,129 | $0 | $-37,985,738 |
| Change In Working Capital | $2,921,847 | $-440,657 | $-261,355 | $379,937 |
| Change In Other Working Capital | $-310,581 | - | - | - |
| Change In Payables And Accrued Expense | $766,835 | $1,539,259 | $1,854,193 | $294,833 |
| Change In Accrued Expense | $834,157 | $690,290 | $1,289,024 | $215,679 |
| Change In Payable | $-67,322 | $848,969 | $565,169 | $79,154 |
| Change In Account Payable | $-67,322 | $848,969 | $565,169 | $79,154 |
| Change In Prepaid Assets | $638,355 | $-641,089 | $-1,200,144 | $85,104 |
| Change In Receivables | $1,827,238 | $-1,338,827 | $-915,404 | $0 |
| Stock Based Compensation | $1,448,634 | $1,405,722 | $407,632 | $333,835 |
| Amortization Of Securities | $-854,077 | $-1,205,197 | $0 | $-208,577 |
| Net Income From Continuing Operations | $-26,966,367 | $-16,290,695 | $-2,171,873 | $-5,803,047 |
| Unrealized Gain Loss On Investment Securities | - | $0 | $-5,424,251 | $2,389,000 |
| Pension And Employee Benefit Expense | - | - | $0 | $127,516 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Sale Of PPE | - | - | - | $0 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
| Depreciation Amortization Depletion | - | - | - | $0 |
| Depreciation And Amortization | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Depreciation | - | - | - | - |
Fetched: 2026-06-17